News Polpharma in pole position for biosimilar Tysabri in Europe Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen's blockbuster multiple sclerosis therapy
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.